Navigation Links
EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States
Date:10/29/2008

Serono an excellent strategic partner to bring the value of tesamorelin to patients in need, post approval," commented Mr. Yves Rosconi, President and CEO of Theratechnologies.

Tesamorelin is a growth hormone-releasing factor analogue with therapeutic potential in a variety of anabolic and lipolytic indications and is in the final stages of its second Phase 3 clinical trial to assess the safety and efficacy when used to reduce visceral adipose tissue in HIV patients with lipodystrophy. The purpose of the study is to confirm the results of the first Phase 3 study, concluded in October 2007.

Terms of the Agreement

Under the terms of the agreement, Theratechnologies will receive an upfront payment of US$30 million which includes a license fee of US$22 million and an equity investment of US$8 million in Theratechnologies common stock at a price of $3.67USD [$4.73CAD] per share by Merck KGaA, providing Merck KGaA a 3.6% ownership in Theratechnologies. Theratechnologies may receive up to US$215 million in total payments, including the upfront payment and payments based on the achievement of certain development, regulatory and sales milestones. Theratechnologies will be entitled to receive increasing royalties on annual net sales of tesamorelin in the US.

Theratechnologies will be responsible for conducting research and development for additional indications. EMD Serono will have the option to co-develop and commercialize additional indications for tesamorelin in the US. EMD Serono will equally share in the development costs related to such additional indications if it exercises its option. Theratechnologies will, in such case, also have the right, subject to EMD Serono's agreement, to opt to co-promote such additional indications.

Consummation of this transaction is subject to customary closing conditions and notification to, and regulatory review by, the US Federal Trade Commission and US Department of Justice under the U.S. Hart-Scott-
'/>"/>

SOURCE EMD Serono, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
2. InterPage L.P. Announces New Enhancements to Enterprise 101 Messaging Solution
3. ATS Medical Announces Third Quarter 2008 Earnings Release Date and Conference Call
4. Animal Health International, Inc. Announces Its First Quarter Fiscal Year 2009 Earnings Release Date and Conference Call Information
5. Sonic Innovations Announces Results for Third Quarter 2008
6. WellPoint Announces Appearances at Upcoming Conferences
7. Beckman Coulter Announces Third Quarter 2008 Results
8. Align Technology Announces Third Quarter Fiscal 2008 Results
9. Rochester Medical Announces Fourth Quarter 2008 Earnings Conference Call November 6, 2008
10. IRIDEX Announces Third Quarter 2008 Conference Call and Release Date
11. Harvest Technologies Announces Patient Education Website, www.CLIclinicalstudy.com : Supports first randomized, placebo-controlled clinical trial in the U.S. using autologous adult stem cells to treat patients with end-stage Critical Limb Ischemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... people both exercise more and drink more , Study ... activity , Findings differ from past research on physical ... Medicine study finds that on days when people exercise ... more alcohol, too. , This is the only study ... for self-reporting physical activity and alcohol use. , "Monday ...
(Date:9/22/2014)... (HealthDay News) -- Teens and young adults at risk ... to help prevent risky sexual behaviors, according to new ... Every year, about 20 million new sexually transmitted infections ... States. About half involve people between 15 and 24 ... Its new report, published Sept. 22 in Annals ...
(Date:9/22/2014)... ARBOR, Mich. A surprising new study pulls back ... in health care: differences in payment and income between ... who don,t. , Contrary to perception, the research ... to favor surgeons and other procedure-performing doctors. , The ... simple difference in pay per minute explains why doctors ...
(Date:9/22/2014)... New York, NY (PRWEB) September 22, 2014 ... pain on the side of the hip , ... for hip bursitis treatment in Manhattan. This treatment is now offered ... bursitis, which is also called trochanteric bursitis, occurs when ... is a fluid-filled sac in the hip, between the ...
(Date:9/22/2014)... Reinberg HealthDay Reporter MONDAY, ... all children aged 6 months and older be vaccinated for ... updated their influenza vaccine recommendations to advise that the youngest ... immunity. The AAP also wants parents of children aged 2 ... vaccine instead of the flu shot if it,s readily available. ...
Breaking Medicine News(10 mins):Health News:We drink more alcohol on gym days 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 3
... cancer is the most common cancer diagnosed among men in ... There are several // treatment options, but new research shows ... , Doctors hope that the drug -- finasteride ... smaller doses, it’s commonly known as Propecia for baldness. It ...
... A new study finds angioplasty should be the treatment ... hospital they initially go to doesn’t offer angioplasty// services ... for treatment. ,Research has shown heart attack patients ... open up the clogged blood vessel that caused the ...
... New research reports, patients who were treated for depression ... vitamin B12 in their blood.// ,An increasing amount ... B and depression, but the specifics have not been ... relationship of vitamin B12 and the treatment of depression. ...
... A new study shows people who suffer from migraine headaches ... which are areas of the brain where the tissue has ... ages 30 to 60. They grouped the patients into categories ... no visual difficulties. A control group was also included in ...
... new study finds people who participated in a cardiac-rehab program ... rate // as those of the same age and sex ... about half of the deaths that occurred among patients in ... cardiac-rehab program. ,The investigation involved about 1,800 patients. Nearly ...
... from extremely low body fat whether due to strenuous ... from treatment with the appetite-and-weight-regulation hormone leptin.// The study ... instances of infertility. ,Leptin is produced in fat ... then travels to the brain and plays a role ...
Cached Medicine News:
(Date:9/22/2014)... 2014  Aethlon Medical, Inc. (OTCQB: AEMD), the ... infectious disease, cancer and other life-threatening conditions, disclosed ... (DARPA) has informed the Company that it plans ... four of a five-year $5.9 million contract that ... under DARPA,s Dialysis-Like Therapeutics (DLT) program. ...
(Date:9/22/2014)... Md. , Sept. 22, 2014  Neuralstem, Inc. (NYSE ... MD, site investigator at Emory University, presented long-term follow ... human neural stem cells in the treatment of amyotrophic ... The presentation, which occurred at the Annual Symposium on ... Canada , on Friday, and was not open ...
(Date:9/22/2014)... Pa. , Sept. 22, 2014  Olympus, ... innovative solutions for medical and surgical procedures, among ... a deal with Munich -based ... Kick ® Navigation. This agreement applies to ... for cross-disciplinary U.S. sales and all distribution outside ...
Breaking Medicine Technology:Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4
... China, Dec. 27, 2011 /PRNewswire-Asia/ -- China Botanic ... ("China Botanic" or the "Company"), a developer, manufacturer ... Chinese Medicines ("TCM") in China, today announced that ... the 66th PHARMCHINA fair ("the Fair") recently held ...
... Reportlinker.com announces that a new ... its catalogue: Europe ... 2017- Glucose Monitoring and Insulin Delivery ... Europe Diabetes Care Devices ...
Cached Medicine Technology:China Botanic Exhibits All-Natural Anti-depressant Products at the 66th PHARMCHINA Fair 2China Botanic Exhibits All-Natural Anti-depressant Products at the 66th PHARMCHINA Fair 3Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 2Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 3Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 4Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 5Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 6Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 7Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 8Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 9Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 10Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 11Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 12
Bechert-McPherson tying forceps, angled, 10 mm tying platforms....
Girard curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 99 mm....
Curved tying forceps made of titanium has curved shafts with 6 mm V-grove tying platforms, width of shafts 0,5 mm, TCI platforms, flat handle, width 10 mm, overall length 103 mm....
Straight tying spring forceps made of titanium, delicate smooth jaws, length 10 mm, TCI jaws with round handle, diam. 8 mm and overall length 115 mm....
Medicine Products: